

Structure-based drug design studies of the interactions of *ent*-kaurane diterpenes derived from *Wedelia paludosa* with the *Plasmodium falciparum* sarco/endoplasmic reticulum Ca²⁺-ATPase PfATP6

Daniel Silqueira Martins Guimarães¹, Amanda Luisa da Fonseca^{1,2,3}, Ronan Batista⁴, Moacyr Comar Junior³, Alaíde Braga de Oliveira⁵, Alex Gutterres Taranto², Fernando de Pilla Varotti^{1/+}

¹Núcleo de Pesquisa em Química Biológica ²Laboratório de Química Farmacêutica Medicinal ³Laboratório de Modelagem Molecular, Universidade Federal de São João del-Rei, Divinópolis, MG, Brasil ⁴Departamento de Química Orgânica, Instituto de Química, Universidade Federal da Bahia, Salvador, BA, Brasil ⁵Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil

Malaria is responsible for more deaths around the world than any other parasitic disease. Due to the emergence of strains that are resistant to the current chemotherapeutic antimalarial arsenal, the search for new antimalarial drugs remains urgent though hampered by a lack of knowledge regarding the molecular mechanisms of artemisinin resistance. Semisynthetic compounds derived from diterpenes from the medicinal plant Wedelia paludosa were tested in silico against the Plasmodium falciparum Ca²⁺-ATPase, PfATP6. This protein was constructed by comparative modelling using the three-dimensional structure of a homologous protein, I1WO, as a scaffold. Compound 21 showed the best docking scores, indicating a better interaction with PfATP6 than that of thapsigargin, the natural inhibitor. Inhibition of PfATP6 by diterpene compounds could promote a change in calcium homeostasis, leading to parasite death. These data suggest PfATP6 as a potential target for the antimalarial ent-kaurane diterpenes.

Key words: malaria - *ent*-kaurane diterpenes - PfATP6 - docking - computer aided-drug design

Malaria is the most widespread infectious parasitic disease around the world (WHO 2013). The burden of emerging parasites resistant to artemisinin combination therapies threatens global efforts to control malaria, making the need for new antimalarial drugs urgent (Miller et al. 2013). However, the molecular mechanisms of artemisinin resistance are unknown (Nunes-Alves 2014). Among the numerous genes involved in artemisinin resistance, PfATP6, a sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) homologue expressed in *Plasmodium falciparum*, has been suggested as a possible target of artemisinin (Valderramos et al. 2010, Cui et al. 2012).

Overcoming the major difficulties in the development of new antimalarial candidates relies on efficient candidate synthesis and a better understanding of the mechanism of action of defined targets (Médebielle 2014). In this context, our research group recently demonstrated the in vitro antiplasmodial activity of oxidised/epoxidised *ent*-kaurane diterpene derivatives obtained from the naturally occurring *ent*-kaurenes of *Wedelia paludosa* DC (Batista et al. 2013). Due to the selective antimalarial activity exhibited by these compounds and knowing that diterpenes induce calcium overload in myocytes (Sun et

al. 2014) we investigated the interaction between the *ent*-kaurane diterpenes and PfATP6 (Gardner et al. 2002). SERCA are crucial for calcium signalling in malarial parasites (Furuyama et al. 2014, Krishna et al. 2014). Calcium signalling is associated with the regulation of many processes during the parasite life cycle, including modulation of kinase activity and synchronisation of the intraerythrocytic cycle (Bagnaresi et al. 2012). Molecular mechanisms that maintain parasite calcium homeostasis are controlled by proteins such as PfATP6 (Krishna et al. 2010). Any alteration to calcium homeostasis, triggered by the inhibition of PfATP6, could promote an increase in cytoplasmic calcium, leading to the activation of the metacaspase PfMCA-1 (Meslin et al. 2011). This mode of action could provide a new strategy to design new pro-apoptotic antimalarial drugs.

Thus, the aim of this study was to construct the PfATP6 enzyme model and perform a rigid and flexible molecular docking analysis of synthetic and semisynthetic diterpenes derived from *W. paludosa* DC.

Initially, the primary sequence of the PfATP6 was obtained from the *Plasmodium* genomics Resource (plasmodb.org/plasmo/). Subsequently, a three-dimensional model was built following a comparative modelling approach. The model was constructed using SwissPDB Viewer 3.7 following a standard protocol as previously described (Bordoli et al. 2009): (i) load the primary sequence of PfATP6, (ii) search for templates against Protein Data Bank (Berman et al. 2013) and (iii) perform structural alignment and submit it to the Swiss Model Server. In this process, the atomic coordinates of thapsigargin (TG), the natural SERCA inhibitor, were transferred from I1WO (Toyoshima & Nomura 2002)

doi: 10.1590/0074-02760140415

Financial support: FAPEMIG, CNPq

+ Corresponding author: varotti@ufsj.edu.br

Received 4 November 2014

Accepted 29 January 2015




Fig. 1: three-dimensional structure of the mammalian Ca^{2+} -ATPase 1IWO (A) and parasite PfATP6 model (B).

TABLE

Rigid and flexible binding energy (Kcal/mol) of molecular docking between *ent*-kaurane diterpenes (8, 9 and 21) and thapsigargin against PfATP6 and 1IWO

Compounds	1IWO	PfATP6	1IWO	PfATP6
	Rigid		Flexible	
8	-7.6	-7.7	-7.1	-6.6
9	-7.6	-7.8	-6.6	-6.3
21	-9.5	-8.4	-7.4	-6.8
Thapsigargin	-7.7	-7.2	-5.8	-4.7

to build the model. The resultant model was refined by AMBER (Case et al. 2010) using the *ff03* force field (Salomon-Ferrer et al. 2013). First, the parameters of TG were determined using the antechamber program and AM1-BCC charges, in which the atom types were assigned by the general amber force field (gaff). Second, the complex enzyme (PfATP6-TG) was prepared by the Leap program, constructing the topological and coordinate files. The complex enzyme was minimised in vacuum followed by application of the generalised Born implicit solvent model with 5,000 steep descent steps and 5,000 conjugate gradient steps in each environment (Lee & Duan 2004). Subsequently, 59 structures were constructed and refined by the semiempirical PM6 (Stewart 2007) method (Bikadi & Hazai 2009) implemented in Gaussian 09 W software (Frisch et al. 2009). The ligands (Supplementary Fig. 1) and molecular targets were prepared by MGL Tools software using a standard protocol (Trott & Olson 2010). A grid box was constructed around the ligand and was sufficiently large to cover the entire binding site to limit the docking space (Supplementary Table I). In sequence, TG was re-docked into

the built model to evaluate the docking methodology (Supplementary Fig. 2). Two distinct approaches were used, rigid and flexible docking. After the rigid docking, the amino acid residues within 4.5 Å of the experimental ligand were chosen for flexible docking (Supplementary Table II). All docking simulations were carried out using AutoDock Vina software (Trott & Olson 2010). The exhaustiveness was set to 8 to improve the docking search. Finally, DS Visualizer v.4.0 (Accelrys Software Inc, USA) was used to show the docking results of the binding conformations (Leite et al. 2013).

A preliminary search indicated three main templates on PDB: 2O9J, 3BA6 and 1IWO, with 43%, 49% and 43.5% identity, respectively. All of them were used as a template to build the model (Fig. 1) using Swiss Model Project Mode (Bordoli et al. 2009, Naik et al. 2011).

Sequence alignment between PfATP6 and the templates showed a region with low similarity that was removed from PfATP6 to build the model. The PfATP6 refined model was evaluated based on the root-mean-square deviation (RMSD) value of the Ca coordinates and the Ramachandran Plot generated by PROCHECK software (Laskowski et al. 1993). Both methods compared against 1IWO showed an RMSD value of 1.61 Å and 87% of residues in the allowed regions; the corresponding percentage for the 1IWO crystal structure was 77.3%. This model is composed of three cytoplasmic domains, denoted as the actuator, phosphorylation and nucleotide binding domains; in addition, there are 10 transmembrane segments denoted as M1 to M10. Initially, the re-docking process showed the structural differences in the natural ligand before and after the molecular docking. The RMSD score was 1.12 Å, indicating that the structures of the molecules are similar to each other. The limit value accepted by the docking approach is 2.0 Å (Trott & Olson 2010). As a result, AutoDock Vina software was used to generate the binding energies of diterpenes and the two enzymes.

The binding energies of the enzymes PfATP6 and 1IWO, as well as those of *ent*-kaurane diterpenes (8, 9 and 21) and TG are shown in Table. The three *ent*-kaurane diterpenes shown in Table were active against *P. falciparum* in vitro (Batista et al. 2013). Compound 21 was the most active, with a 50% inhibitory concentration (IC_{50}) value of 5.4 µM. Compounds 8 and 9 displayed the highest selective antimalarial activity, with selective index values of 1,238.5 and 810.2, respectively. Compounds 8 and 9 exhibited similar binding energies to those of TG. Compound 21 showed the best docking results against PfATP6 and 1IWO, indicating a stronger interaction with the targets than that of TG, the natural inhibitor. Fig. 2 shows the interaction of TG and compound 21 with the PfATP6 binding site.

These data suggest PfATP6 as a potential target for the semisynthetic antimalarial diterpene epoxides derived from naturally occurring *ent*-kauranes from *W. paludosa*. The three *ent*-kaurane diterpenes presented similar binding energy values to those obtained with mammalian and parasite enzyme models. Further optimisation of these lead compounds may provide a more potent and selective antimalarial drug.




Fig. 2: interactions of thapsigargin (A) and *ent*-kaurane diterpene 21 (B) with the PfATP6 binding site.

REFERENCES

- Bagnaesi P, Nakabashi M, Thomas AP, Reiter RJ, Garcia CRS 2012. The role of melatonin in parasite biology. *Mol Biochem Parasitol* 181: 1-6.
- Batista R, Garcia PA, Castro MA, del Corral JMM, Speziali NL, Varotti FP, de Paula RC, Garcia-Fernández LF, Francesch A, San Feliciano A, de Oliveira AB 2013. Synthesis, cytotoxicity and antiplasmodial activity of novel *ent*-kaurane derivatives. *Eur J Med Chem* 62: 168-176.
- Berman HM, Kleywegt GJ, Nakamura H, Markley JL 2013. The future of the protein data bank. *Biopolymers* 99: 218-222.
- Bikadi Z, Hazai E 2009. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. *J Cheminform* 1: 15.
- Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, Schwede T 2009. Protein structure homology modeling using SWISS-MODEL workspace. *Nat Protoc* 4: 1-13.
- Case D, Darden T, Cheatham TI, Simmerling C, Wang J, Duke R, Luo R, Walker R, Zhang W, Merz K, Roberts B, Wang B, Hayik S, Roitberg A, Seabra G, Kolossvai I, Wong K, Paesani F, Vanicek J, Liu J, Wu X, Brozell S, Steinbrecher T, Gohlke H, Cai Q, Ye X, Hsieh M-J, Cui G, Roe D, Mathews D, Seetin M, Sagui C, Babin V, Luchko T, Gusarov S, Kovalenko A, Kollman P 2010. *AMBER II*, University of California, San Francisco, 300 pp.
- Cui L, Wang Z, Jiang H, Parker D, Wang H, Su X, Cui L 2012. Lack of association of the S769N mutation in *Plasmodium falciparum* SERCA (PfATP6) with resistance to artemisinins. *Antimicrob Agents Chemother* 56: 2546-2552.
- Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JAJ, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam MJ, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ö, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ 2009. Gaussian 09, Gaussian Inc, Wallingford CT.
- Furuyama W, Enomoto M, Mossaad E, Kawai S, Mikoshiba K, Kawazu S 2014. An interplay between 2 signaling pathways: melatonin-cAMP and IP3-Ca²⁺ signaling pathways control intraerythrocytic development of the malaria parasite *Plasmodium falciparum*. *Biochem Biophys Res Commun* 446: 125-131.
- Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B 2002. Genome sequence of the human malaria parasite *Plasmodium falciparum*. *Nature* 419: 498-511.
- Krishna S, Pulcini S, Fatih F, Staines H 2010. Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. *Trends Parasitol* 26: 517-523.
- Krishna S, Pulcini S, Moore CM, Teo BH-Y, Staines HM 2014. Pumped up: reflections on PfATP6 as the target for artemisinins. *Trends Pharmacol Sci* 35: 4-11.
- Laskowski RA, MacArthur MW, Moss DS, Thornton JM 1993. PROCHECK: a program to check the stereochemical quality of protein structures. *J Appl Crystallogr* 26: 283-291.
- Lee MC, Duan Y 2004. Distinguish protein decoys by using a scoring function based on a new AMBER force field, short molecular dynamics simulations and the generalized born solvent model. *Proteins* 55: 620-634.
- Leite FHA, da Fonseca AL, Nunes RR, Comar Jr M, Varotti FP, Taranto AG 2013. Malária: dos velhos fármacos aos novos alvos moleculares. *Biol Biomed Rep* 2: 59-76.
- Mèdebielle M 2014. The medicinal chemistry and drug development of novel antimalarials. *Curr Top Med Chem* 14: 1635-1636.
- Meslin B, Beavogui AH, Fasel N, Picot S 2011. *Plasmodium falciparum* metacaspase PfMCA-1 triggers a z-VAD-fmk inhibitable protease to promote cell death. *PLoS ONE* 6: 1-11.
- Miller LH, Ackerman HC, Su X, Wellems TE 2013. Malaria biology and disease pathogenesis: insights for new treatments. *Nat Med* 19: 156-167.
- Naik PK, Srivastava M, Bajaj P, Jain S, Dubey A, Ranjan P, Kumar R, Singh H 2011. The binding modes and binding affinities of artemisinin derivatives with *Plasmodium falciparum* Ca²⁺-ATPase (PfATP6). *J Mol Model* 17: 333-357.
- Nunes-Alves C 2014. Propelling artemisinin resistance. *Nat Rev Microbiol* 13: 1.
- Salomon-Ferrer R, Case DA, Walker RC 2013. An overview of the amber biomolecular simulation package. *Wiley Interdiscip Rev Comput Mol Sci* 3: 198-210.

- Stewart JJP 2007. Optimization of parameters for semiempirical methods. V. Modification of NDDO approximations and application to 70 elements. *J Mol Model* 13: 1173-1213.
- Sun G-B, Sun H, Meng X-B, Hu J, Zhang Q, Liu B, Wang M, Xu H-B, Sun X-B 2014. Aconitine-induced Ca^{2+} overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats. *Toxicol Appl Pharmacol* 279: 8-22.
- Toyoshima C, Nomura H 2002. Structural changes in the calcium pump accompanying the dissociation of calcium. *Nature* 418: 605-611.
- Trott O, Olson AJ 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. *J Comput Chem* 31: 455-461.
- Valderramos SG, Scandfield D, Uhlemann A, Fidock DA, Krishna S 2010. Investigations into the role of the *Plasmodium falciparum* SERCA (PfATP6) L263E mutation in artemisinin action and resistance. *Antimicrob Agents Chemother* 54: 3842-3852.
- WHO - World Health Organization 2013. World Malaria Report 2013. Available from: who.int/malaria/publications/world_malaria_report_2013/en/.

TABLE I
Grid box size and position for both enzymes models

	Centre position			Box size		
	x	y	z	x	y	z
IIWO	-5.077	-47.902	8.882	28	26	30
PfATP	-4.857	-24.528	7.832	26	32	28

TABLE II
Flexible amino acids of the active sites from the mammalian and parasite enzymes

IIWO			PfATP6		
Residue	Symbol	Position	Residue	Symbol	Position
Leucine	LEU	253	Isoleucine	ILE	251
Glutamate	GLU	255	Leucine	LEU	253
Phenylalanine	PHE	256	Phenylalanine	PHE	254
Glutamine	GLN	259	Glutamine	GLN	257
Leucine	LEU	260	Leucine	LEU	258
Valine	VAL	263	Isoleucine	ILE	261
Isoleucine	ILE	761	Isoleucine	ILE	748
Isoleucine	ILE	765	Isoleucine	ILE	752
Aspartate	ASN	768	Aspartate	ASN	755
Valine	VAL	769	Isoleucine	ILE	756
Valine	VAL	772	Valine	VAL	759
Valine	VAL	773	Phenylalanine	PHE	763
Phenylalanine	PHE	776	Leucine	LEU	815
Leucine	LEU	828	Isoleucine	ILE	816
Isoleucine	ILE	829	Leucine	LEU	821
Phenylalanine	PHE	834	Tyrosine	TYR	824
Tyrosine	TYR	837	Isoleucine	ILE	825
Methionine	MET	838	-	-	-




Fig. 1: chemical structure of *ent*-kaurane diterpenes 8, 9, 21 and the natural inhibitor thapsigargin.




Fig. 2: redocking results. In green colour is the crystallographic PDB structure and in black is the docked one.